Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2026-02-25 @ 6:29 PM
Study NCT ID:
NCT04864834
Status:
COMPLETED
Last Update Posted:
2024-03-26
First Post:
2021-04-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Sponsor:
Sandoz
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-12
Start Date Type:
ACTUAL
Primary Completion Date:
2022-07-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-05-10
Completion Date Type:
ACTUAL
First Submit Date:
2021-04-15
First Submit QC Date:
None
Study First Post Date:
2021-04-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-01-25
Results First Submit QC Date:
None
Results First Post Date:
2024-03-26
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2024-03-26
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-02-29
Last Update Post Date:
2024-03-26
Last Update Post Date Type:
ACTUAL